- Home
- NGD vs MYGN Comparison
NGD vs MYGN Comparison
Compare NGD & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGD
- MYGN
- Stock Information
- Founded
- NGD N/A
- MYGN 1991
- Country
- NGD Canada
- MYGN United States
- Employees
- NGD N/A
- MYGN N/A
- Industry
- NGD
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NGD
- MYGN Health Care
- Exchange
- NGD Nasdaq
- MYGN Nasdaq
- Market Cap
- NGD 2.0B
- MYGN 2.0B
- IPO Year
- NGD 2004
- MYGN 1995
- Fundamental
- Price
- NGD $2.81
- MYGN $12.57
- Analyst Decision
- NGD Buy
- MYGN Hold
- Analyst Count
- NGD 4
- MYGN 12
- Target Price
- NGD $3.04
- MYGN $23.92
- AVG Volume (30 Days)
- NGD 7.7M
- MYGN 1.0M
- Earning Date
- NGD 02-19-2025
- MYGN 02-25-2025
- Dividend Yield
- NGD N/A
- MYGN N/A
- EPS Growth
- NGD N/A
- MYGN N/A
- EPS
- NGD 0.02
- MYGN N/A
- Revenue
- NGD $861,500,000.00
- MYGN $823,600,000.00
- Revenue This Year
- NGD $20.35
- MYGN $13.73
- Revenue Next Year
- NGD $34.38
- MYGN $4.34
- P/E Ratio
- NGD $118.66
- MYGN N/A
- Revenue Growth
- NGD 14.85
- MYGN 12.15
- 52 Week Low
- NGD $1.09
- MYGN $12.17
- 52 Week High
- NGD $3.25
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- NGD 58.24
- MYGN 32.55
- Support Level
- NGD $2.67
- MYGN $12.17
- Resistance Level
- NGD $2.83
- MYGN $15.08
- Average True Range (ATR)
- NGD 0.11
- MYGN 0.80
- MACD
- NGD 0.03
- MYGN -0.03
- Stochastic Oscillator
- NGD 79.79
- MYGN 13.75
About NGD New Gold Inc.
New Gold Inc participates in the development and operation of intermediate mining properties. The company has a portfolio of two primary assets: the Rainy River Mine and the New Afton Mine in Canada. The company also owns the Cerro San Pedro Mine in Mexico. The company derives revenue from the sale of gold, copper, and silver.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.